We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-0.07%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$147M
AUM Growth
-$4.71M
Cap. Flow
+$154K
Cap. Flow %
0.1%
Top 10 Hldgs %
83.52%
Holding
56
New
7
Increased
6
Reduced
13
Closed
3

Top Buys

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$824K
2
NKTR icon
Nektar Therapeutics
NKTR
+$730K
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$645K
4
IFRX icon
InflaRx
IFRX
+$553K
5
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$486K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.91M
2
XLRN
Acceleron Pharma
XLRN
+$474K
3
CORT icon
Corcept Therapeutics
CORT
+$444K
4
SHPG
Shire pic
SHPG
+$403K
5
SLDB icon
Solid Biosciences
SLDB
+$287K

Sector Composition

Rank Sector Weight
1 Healthcare 95.63%
2 Energy 3.26%
3 Consumer Staples 0.26%
4 Industrials 0.25%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
51
Cytokinetics
CYTK
$10.9B
$83K 0.06%
10,000
– –
WKHS icon
52
Workhorse Group
WKHS
$30.2M
$46K 0.03%
8
-9
-53% -$69.1K
QTNT
53
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-993
Closed -$187K
ABLX
54
DELISTED
Ablynx NV
ABLX
– –
-5,000
Closed -$273K
SHPG
55
DELISTED
Shire pic
SHPG
– –
-2,700
Closed -$403K
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Birchview Capital held 56 positions worth $147M, down 3.1% from $152M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Birchview Capital's Q2 2018 filing shows 7 new, 6 increased, 13 reduced and 3 closed positions. Its largest new stake was Karyopharm Therapeutics: 3,333 shares worth $850K. The largest sale was Celgene Corp, an estimated $1.91M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2018 buy was Karyopharm Therapeutics: 3,333 shares worth $850K.
  • Birchview Capital added most to Arena Pharmaceuticals Inc in Q2 2018, an estimated $645K increase.
  • Birchview Capital's biggest Q2 2018 reduction was Celgene Corp, cutting an estimated $1.91M.
  • Birchview Capital fully exited Shire pic in Q2 2018, selling an estimated $403K.
  • Birchview Capital's ten largest holdings make up 84% of its $147M portfolio in Q2 2018.
  • Birchview Capital opened 7 new positions and closed 3 in Q2 2018.
  • Birchview Capital's portfolio value fell 3.1% quarter-over-quarter to $147M.

Based on Birchview Capital's 13F filing for Q2 2018, filed 2 Aug 2018.